Research Site

Zion, Illinois 60099

3 studies enrolling now · 8 studies all time

What they study most

Advanced Clear Cell Renal Cell Carcinoma, Carcinoma, Esophageal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Metastases, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, Neoplasm, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC)

Studies at this site

• Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma — Recruiting now
• Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 — Recruiting now
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations — Recruiting now
• A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features — Running, not enrolling
• A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations — Completed
• PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response — Completed
• Iressa Expanded Access Program (EAP) — Completed
• CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy — Completed